Known targets — ChEMBL curated mechanism
The experimentally established mechanism targets of Trifluoroacetic Acid. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | FAAH | O00519 | 12/20 | 0.47 |
| ▸ | EPHX1 | P07099 | 1/20 | 0.46 |
| ▸ | CES1 | P23141 | 9/20 | 0.45 |
| ▸ | CES2 | O00748 | 7/20 | 0.45 |
| ▸ | MEN1 | O00255 | 1/20 | 0.45 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.45 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.45 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.45 |
| ▸ | FUCA1 | P04066 | 1/20 | 0.43 |
| ▸ | PLA2G6 | O60733 | 1/20 | 0.39 |
| ▸ | S1PR2 | O95136 | 1/20 | 0.38 |
| ▸ | S1PR1 | P21453 | 1/20 | 0.38 |
| ▸ | S1PR3 | Q99500 | 1/20 | 0.38 |
| ▸ | S1PR5 | Q9H228 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Trifluoroacetic Acid SCHEMBL28395953 | 0.96 | FAAH (0.50) | FAAHEPHX1CES1CES2MEN1 | |
| Trifluoroacetic Acid SCHEMBL28392985 | 0.93 | FAAH (0.41) | FAAHEPHX1CES1CES2MEN1 | |
| Trifluoroacetic Acid SCHEMBL28399119 | 0.91 | TP53 (0.40) | FAAHEPHX1CES1CES2MEN1 | |
| Trifluoroacetic Acid SCHEMBL28666896 | 0.89 | TP53 (0.38) | FAAHEPHX1CES1CES2MEN1 | |
| Trifluoroacetic Acid SCHEMBL5880385 | 0.89 | FAAH (0.56) | FAAHEPHX1CES1CES2MEN1 | |
| Trifluoroacetic Acid SCHEMBL5238463 | 0.88 | FAAH (0.44) | FAAHEPHX1CES1CES2MEN1 | |
| Trifluoroacetic Acid SCHEMBL12520341 | 0.87 | FAAH (0.54) | FAAHEPHX1CES1CES2MEN1 | |
| Heptane SCHEMBL1776021 | 0.87 | FAAH (0.58) | FAAHEPHX1CES1CES2MEN1 | |
| Trifluoroacetic Acid SCHEMBL2242176 | 0.87 | TP53 (0.44) | FAAHEPHX1CES1CES2MEN1 | |
| Trifluoroacetic Acid SCHEMBL28562828 | 0.86 | FAAH (0.42) | FAAHEPHX1CES1CES2MEN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 17 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-111413435-B | Detection method of tamsulosin hydrochloride intermediate | 珠海润都制药股份有限公司 | 2022-07-08 | — | — | CN | claimed |
| CN-111413435-A | Detection method of tamsulosin hydrochloride intermediate | 珠海润都制药股份有限公司 | 2020-07-14 | — | — | CN | claimed |
| CN-106442765-A | Method for detecting isomers of dexmedetomidine hydrochloride crude product | 辰欣药业股份有限公司 | 2017-02-22 | — | — | CN | claimed |
| CN-115452993-A | Separation and detection method of isomers of pasiclovir intermediate | 南京药坦生物科技有限公司 | 2022-12-09 | — | — | CN | disclosed |
| CN-111413435-B | Detection method of tamsulosin hydrochloride intermediate | 珠海润都制药股份有限公司 | 2022-07-08 | — | — | CN | disclosed |
| CN-111175387-B | Method for detecting milnacipran isomer | 成都康弘药业集团股份有限公司 | 2022-06-07 | — | — | CN | disclosed |
| CN-111413435-A | Detection method of tamsulosin hydrochloride intermediate | 珠海润都制药股份有限公司 | 2020-07-14 | — | — | CN | disclosed |
| CN-111323493-A | Method for detecting enantiomer of posaconazole starting material | 武汉赛沃医药科技有限公司 | 2020-06-23 | — | — | CN | disclosed |
| CN-111175387-A | Method for detecting milnacipran isomer | 成都康弘药业集团股份有限公司 | 2020-05-19 | — | — | CN | disclosed |
| CN-109239231-A | A kind of chiral isomer analysis method | 药源生物科技（启东）有限公司 | 2019-01-18 | — | — | CN | disclosed |
| CN-106442765-A | Method for detecting isomers of dexmedetomidine hydrochloride crude product | 辰欣药业股份有限公司 | 2017-02-22 | — | — | CN | disclosed |
| EP-1295870-B1 | SUPLATAST TOSILATE CRYSTALS | TAIHO PHARMACEUTICAL CO LTD (JP) | 2007-12-19 | — | — | EP | disclosed |
| US-7138140-B2 | Suplatast tosilate crystals | TAIHO PHARMACEUTICAL CO., LTD. (JP) | 2006-11-21 | — | — | US | disclosed |
| CN-1205182-C | suplatast tosilate crystals | TAIHO PHARMACEUTICAL CO LTD (JP) | 2005-06-08 | — | — | CN | disclosed |
| CN-1461297-A | Suplatast tosilate crystals | TAIHO PHARMACEUTICAL CO LTD (JP) | 2003-12-10 | — | — | CN | disclosed |
| US-20030149105-A1 | Suplatast tosilate crystals | TAIHO PHARMACEUTICAL CO., LTD. (JP) | 2003-08-07 | — | — | US | disclosed |
| EP-1295870-A1 | SUPLATAST TOSILATE CRYSTALS | TAIHO PHARMACEUTICAL COMPANY LIMITED (JP) | 2003-03-26 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030149105-A1 | Suplatast tosilate crystals | SART3, SOST, PRPF19 | FAAH 2851/4885EPHX1 4775/4885CES1 2413/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.